Pfizer has cleared a major hurdle towards bringing biosimilar bevacizumab to the US market by obtaining approval from the Food and Drug Administration for its Zirabev (bevacizumab-bvzr) alternative to Genentech’s Avastin oncology brand. But significant patent barriers remain.
Based on a data package that included a read-out from its ‘Reflections B7391003’ comparative clinical trial, Pfizer has secured FDA...






